Based on the preclinical studies, it might be expected that TAAR1 could be a potential drug target for several neuropsychiatric disorders, including schizophrenia, depression, bipolar disorder, generalized anxiety disorder, addiction, ADHD, Alzheimer’s disorder, etc. [29,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52]. Here, TAAR1 is linked to schizophrenia.